EGFR and non-small cell lung carcinoma: For example, a recent study has evaluated the feasibility and efficacy of longitudinal monitoring of ctDNA as a valuable biomarker for early detection of MRD and to provide identification of the group at high risk for recurrence in resected stages I to IIIA EGFR mutation positive (EGFR-M+) NSCLC [37].